ArticlePloS one2026
Efficacy and safety of Galgeun-tang-ga-cheongung-sinyi for nasal congestion with common cold: A study protocol for randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommon cold is a common respiratory disease caused by a viral infection of the upper respiratory tract, leading to various symptoms including cough, sneezing, nasal congestion, and sore throat. As the medications used to treat the common cold may cause adverse effects such as gastrointestinal symptoms, drowsiness, and decreased concentration, it is necessary to explore alternative treatments for patients with the common cold. The aim of this study is to assess the effectiveness and safety of Galgeun-tang-ga-cheongung-sinyi (GGTCS), an herbal formula used to treat respiratory diseases, as an alternative medicine for nasal congestion with common cold.
methodsThis is a randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial. A total of 176 participants will be recruited and randomly allocated to the GGTCS group and control (placebo) group in a 1:1 allocation ratio. GGTCS or placebo will be administered three times per day for 7 days. The participants will be instructed to discontinue the medicine if the symptoms of the common cold disappear within 7 days of the treatment period and return the remaining medicine to the investigators. The primary outcome measures are changes in the total score of the Wisconsin Upper Respiratory Symptom Survey-21-Korean version (WURSS-21-K) (symptom score + quality of life score) on day 7 compared with baseline. Secondary outcome measures include the total, symptom, and quality of life scores of the WURSS-21-K, nasal congestion severity score, nasal and systemic symptom score visual analogue scale (VAS), duration of common cold symptoms, recovery from common cold, global evaluation of efficacy, and 5-level EuroQol 5-dimensional questionnaire (EQ-5D-5L). The exploratory outcome measure is a questionnaire for common cold pattern identification (QCCPI), and the safety assessment factors include adverse effects, vital signs, electrocardiograms, and clinical laboratory tests. DISCUSSION: The goal of this study is to assess the effectiveness and safety of GGTCS for nasal congestion with the common cold and the clinical use of herbal medicine. The results are expected to help researchers design further clinical trials using herbal medicines to treat the common cold.
trial registrationThis trial was registered on February 28, 2025 at the National Clinical Trial Registry Clinical Research Information Service (https://cris.nih.go.kr) with the identifier number KCT0010251.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.